The Jes-Extender has been clinically tested. NON-SURGICAL PENILE ELONGATION Tractive Elongation of the Penis by Means of Stretching Jørn Ege Siana, MD, Scandinavian Clinic of Plastic Surgery, Copenhagen Study presented at the 1st International Interdisciplinary Symposium on Genitourinary Reconstructive Surgery. April 6th, 7th and 8th 1998 - Barcelona - Spain INTRODUCTION Based on the evidence of human tissue response to stretching a traction device for non-invasive penile lengthening has been designed: The Jes-Extender. TRACTION DEVICE - THE JES- EXTENDER - Basic ring, fastened proximally around the root of the penis, abutting on the symphysis. - Two dynamic metal bars hinged to the ring, connecting it to the silicon-support, fastened around the corona glans at the distal end of the penis. - By gradually increasing the tractive force on the two metal bars a stretching force is exerted on the corporae of a 600-1500 g. MATERIAL AND METHODS - Number of patients: 18 patients ranging from 23-47 years - Inclusion: normal erectile capacity and no penile surgery - Exclusion: chronically diseases - Traction force: 0- 2 weeks - 900-1000 g 2-24 weeks - 1000-1200 g - Treatment period: 12 hours daily 7 days a week 8 to 24 weeks - Follow up: every 2.week

RESULTS IN ERECTION

Average Increase in % with 18 test persons:

CONCLUSIONS

The average result of Jes-Extender treatment was an increase in erect length of 2,8 cm (1.1 Inch) after 1100 hours at 1200 g traction force. The corresponding flaccid increase is 1,9 cm or 0.75 inch. - Preliminary study - All patients achieved penile lengthening after traction with the Jes-Extender - Average lengthening per week was 1,9 mm - No complications - Medical indications a) Non-invasive: hypoplasic penis, Peyronie's disease b) Postoperative: hypospadias / epispadias, penile lengthening procedures

The Jes-Extender has been clinically tested for curing Peyronie´s disease

Tested by
X NATIONAL CONGRESS OF THE SPANISH ASSOCIATION OF ANDROLOGY
(ASOCIACIÓN ESPAÑOLA DE ANDROLOGÌA - ASESA)
March 28, 29 and 30, 2001, Alicante (SPAIN)

Report Title
TREATMENT OF PEYRONIE´S DISEASE
VIA MECHANICAL TRACTION, JES EXTENDER®
A prospective study in 26 males

INTRODUCTION:
The traction force applied upon the tissues results in an adaptation reaction at a structural level, due to the suppression of an inhibitor factor related with cellular division, which thereby results in cellular duplication and therefore, the expansion of the tissues. This principle has successfully been applied for quite some time for different medical purposes, among which the treatment of skin lesions, the loss of tissue and post-radiation scars are the most important. The origin of the fibrotic plaque in Peyronie´s disease still remains an unanswered question. The histological studies carried out so far confirm the presence of high concentrations of type-III collagen in the plaque, having been compared with hyperplastic scar tissue and keloids. The “maturation” of the fibrous tissue scars is produced via the translocation of collagen fibers, which takes place secondary to the traction forces that the fibroblasts oppose to the cellular contraction forces. The higher the concentration of type-III collagen in the fibrotic tissue, the stronger the contraction force is. The continuous mechanical traction on the penis in Peyronie´s disease stimulates cellular division and, therefore, the expansion of the healthy tissues and finally exerts an opposing force to the contraction force of the collagen. 

POPULATION AND METHODS:
A prospective study has been performed in 26 males who had been diagnosed as having Peyronie´s disease and were treated during a 6 month-period with the mechanical traction devise, Jes Extender?, exerting a pressure in the range of 1,200 and 1,500 g. The mean age was 50.8 (30 – 68) years old and the mean evolution time of the disease was 25.6 (2 – 72) months. Multiple fibrotic plaques were identified in 6 cases and just one in 19 patients. The long axis of the plaque was equal to or less than 3 cm in 20 cases; 11 patients referred sensorial disturbances of the penis and 21 presented with erectile dysfunction.

OUTCOMES:
Mean values of the assessed parameters before the enrollment, and at 3 and 6 months after treatment was performed are expressed in Table I.